Acurx Pharmaceuticals Files Prospectus Supplement
Ticker: ACXP · Form: 424B5 · Filed: Apr 16, 2026 · CIK: 0001736243
Sentiment: neutral
Topics: prospectus-supplement, offering, pharmaceuticals
Related Tickers: ACRX
TL;DR
ACRX filed a prospectus supplement, likely for a stock offering. Watch for dilution.
AI Summary
Acurx Pharmaceuticals, Inc. filed a 424B5 prospectus supplement on April 16, 2026, related to its previously filed registration statement. This filing pertains to the potential offering of common stock, though specific dollar amounts or share quantities are not detailed in this excerpt.
Why It Matters
This filing indicates Acurx Pharmaceuticals is preparing to potentially offer more shares of its common stock, which could impact existing shareholders through dilution or signal a need for capital.
Risk Assessment
Risk Level: medium — Prospectus supplements often precede stock offerings, which can lead to dilution for existing shareholders and price volatility.
Key Players & Entities
- Acurx Pharmaceuticals, Inc. (company) — Filer of the 424B5 form
- 0001736243 (company) — CIK number for Acurx Pharmaceuticals, Inc.
- 2026-04-16 (date) — Filing date of the 424B5 form
- 333-288595 (file_number) — File number associated with the registration statement
FAQ
What type of filing is this?
This is a 424B5 filing, which is a prospectus supplement.
Who is the filer?
The filer is Acurx Pharmaceuticals, Inc. (CIK: 0001736243).
When was this filing made?
The filing date was April 16, 2026.
What is the purpose of a 424B5 filing?
A 424B5 filing is used to supplement a previously filed registration statement, typically to provide updated information about securities being offered for sale.
What is the company's business address?
The business address is 259 LIBERTY AVENUE, STATEN ISLAND NY 10305.
Filing Details
This Form 424B5 (Form 424B5) was filed with the SEC on April 16, 2026 regarding Acurx Pharmaceuticals, Inc. (ACXP).